Skandinaviska Enskilda Banken (SEB)
KALV

Skandinaviska Enskilda Banken (SEB)’s KalVista Pharmaceuticals KALV Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-351,305
Closed -$5.68M – 450
2025
Q4 		$5.68M Buy
351,305
+150,314
+75% +$1.99M 0.02% 392
2025
Q3 		$2.45M Buy
200,991
+160,128
+392% +$2.21M 0.01% 530
2025
Q2 		$462K Hold
40,863
– – ﹤0.01% 710
2025
Q1 		$471K Hold
40,863
– – ﹤0.01% 699
2024
Q4 		$343K Hold
40,863
– – ﹤0.01% 732
2024
Q3 		$473K Hold
40,863
– – ﹤0.01% 719
2024
Q2 		$480K Hold
40,863
– – ﹤0.01% 689
2024
Q1 		$483K Buy
+40,863
New +$545K ﹤0.01% 710

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s KALV Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 351,305 shares — an estimated $5.68M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in KALV in Q1 2024 and held it in 8 quarters. The position peaked at $5.68M in Q4 2025. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 351,305 KalVista Pharmaceuticals shares in Q1 2026, an estimated $5.68M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s KalVista Pharmaceuticals position peaked at $5.68M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.